Accreditation/Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This activity is NOT approved for AMA PRA Category 1 Credit™.
Acknowledgment of Commercial SupportThis activity is funded entirely by Physicians’ Education Resource®, LLC.
10th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® Medical Crossfire®
Date/TimeSaturday, October 18, 2014 • 8:30 AM – 10:00 AM
Audience arrival/check-in and breakfast 8:00 AM – 8:30 AM.
16986 Dallas Parkway (northbound side of parkway)
Dallas, TX 75248
OverviewThis program being filmed in front of a live studio audience, will update participants on advances in the field, with a focus on the changing treatment landscape for metastatic melanoma, including both recently approved agents, such as the targeted drugs dabrafenib and trametinib, the BRAF inhibitor vemurafenib, as well as investigational agents, including immunotherapy agents that are available via clinical trials. In a roundtable discussion format, our panel of experts will discuss late-stage investigational agents, such as PD1 and PD-L1 inhibitors, and investigational indications for approved agents. Then they will debate where approved agents fit into current treatment paradigms, focusing on how to sequence the agents in the treatment armamentarium to provide the best possible benefit. Case scenarios presented during the panel discussion will highlight some of the important clinical questions faced in clinical practice. Lastly, the panel will spend time discussing treatment options for advanced basal cell carcinoma.
This educational activity is directed toward medical oncologists, fellows, surgical, radiation oncologists, who treat patients with skin and other cutaneous malignancies. Dermatologists, dermatopathologists and pathologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of skin and other cutaneous malignancies will be invited to participate.
Who Should Attend
You must be logged in to PER to register for this meeting
Or Register for PER now
In case of onsite emergency:
Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19
I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventative measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, or I have been in close contact with anyone that has been diagnosed with COVID-19, then I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities.
I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.
* By checking this box, you have read and understand the above and agree to its terms.